Abiraterone acetate treatment of patients with metastatic castrate-resistant prostate cancer

Introduction: metastatic castrate-resistant prostate cancer is the most complex and serious kind of prostate cancer. Such patients usually receive second-line hormonal therapy sometimes, but usually symptomatic treatment is carried out. Abiraterone acetate, the new hormonal drug, selectively inhibits the enzyme CYP17, thus blocking the synthesis of androgens on all levels, thereby reducing the concentration of androgens. Materials and methods: 17 patients with prostate cancer T1-4N0-1M1 with bone metastases and skeletal regional lymph nodes received abiraterone acetate. We assessed the quality of life of the patients, changes of their level of pain, total serum PSA and testosterone, as well as adverse reactions and toxicity profile. Results: The testosterone synthesis inhibitors achieve castrate levels of testosterone. Abiraterone acetate is the drug of choice as first-line therapy in patients with metastatic castrate-resistant prostate cancer. Abiraterone acetate is also indicated for patients with metastatic castrate-resistant prostate cancer, who have resistance to the first-line chemotherapy. Abiraterone should be obligatory accompanied by castration therapy (LHRH agonists or antagonists in patients not undergoing bilateral orchiectomy).